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Abstract
Introduction The potential usefulness of glucose-insulin
therapy relies to a large extent on the premise that it
prevents hyperglycemia and hyperlipidemia following
cardiac ischemic events.
Methods In this review we evaluate the literature concerning
plasma glucose and free fatty acids levels during and
following cardiac ischemic events.
Results The data indicate that hyperlipidemia and hyper-
glycemia most likely occur during acute coronary ischemic
syndromes in the conscious state (e.g. acute myocardial
infarction) and less so during reperfusion following CABG
reperfusion. This is in accordance with observations that
glucose-insulin therapy during early reperfusion post
CABG may actually cause hypolipidemia, because sub-
stantial hyperlipidemia does not appear to occur during that
stage of cardiac surgery.
Discussion Considering recent data indicating that hypo-
lipidemia may be detrimental for cardiac function, we
propose that free fatty acid levels during reperfusion post
CABG with the adjunct glucose-insulin therapy need to be
closely monitored.
Conclusion From a clinical point of view, a strategy
directed at monitoring and thereafter maintaining plasma
substrate levels in the normal range for both glucose
(4–6 mM) and FFA (0.2–0.6 mM) as well as stimulation
of glucose oxidation, promises to be the most optimal
metabolic reperfusion treatment following cardiac ischemic
episodes. Future (preclinical and subsequently clinical)
investigations are required to investigate whether the
combination of glucose-insulin therapy with concomitant
lipid administration may be beneficial in the setting of
reperfusion post CABG.
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Introduction
Ever since the introduction of glucose-insulin-potassium
therapy in the setting of cardiac ischemic diseases [1], this
technique has gone through alternating periods of varying
attention. Although originally devised to prevent intra-
myocardial hypokalemia during ischemia and reperfusion,
the therapy is nowadays mainly advocated to reduce
hyperglycemia and hyperlipidemia which have been
deemed to be present during the reperfusion period.
The first part of this review entails a critical appraisal of
the literature concerning plasma substrate concentrations
following reperfusion of ischemic cardiac events. We hope
to convince the reader that, although plasma levels of free
fatty acids (i.e., non-esterified fatty acids) and glucose may
be elevated during reperfusion, this certainly is not always
observed. Factors affecting substrate availability are highly
influenced by the specific standard operation protocols used
by the hospital (protocols for fasting, anesthesia techniques,
heparin use, inotropic therapy), the anxiety of the organism
(conscious versus anaesthetized) and the medical character-
istics of the patient. The availability of substrates in the
blood stream is a major determinant of myocardial
metabolic activity. Metabolic treatment of the ischemic
heart during reperfusion, therefore, can only be successful
when it is based on accurate knowledge concerning the pre-
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treatment (=baseline) levels of circulating substrates of the
patient.
The second part of this review is directed at how
glucose-insulin therapy may affect substrate availability
during reperfusion and how these changes may affect
cardiac recovery following an ischemic episode through
specific alterations in cardiac metabolism. From a clinical
point of view, a strategy directed at keeping plasma substrate
levels within the normal range (thus preventing both hyper-
and hypoglycemia and hyper-and hypolipidemia) and at
stimulation of glucose oxidation seems to hold the most
promise for optimal treatment of the heart following cardiac
ischemic episodes.
Plasma substrate availability during cardiac ischemic
events
Clinical factors affecting substrates
In the healthy, fed individual, blood glucose levels range
between 4-6 mM (70–110 mg/100 dl) and free fatty acid
(FFA) levels between 0.2–0.6 mM. However, in the peri-
operative condition considerable changes in these substrate
levels may occur as a consequence of the specific operation
protocol. Patients scheduled for elective cardiac operations
are usually requested to refrain from food intake 12–24 h
before the operation. This fasting procedure results in low
insulin levels (removing insulin-inhibition of lipoprotein
lipase (LPL)), increased FFA concentration and decreased
glucose concentration [2, 3]. The next confounding factor is
the type of anesthetic regimen chosen. Many anesthetics
differently affect plasma glucose and insulin levels, with
minor effects on plasma FFA. We recently showed that,
while pentobarbital and sufentanil-propofol were without
effect on plasma glucose concentration, volatile anesthetics
and α2-agonists (e.g. xylazine, medetomidine) resulted in
hyperglycemia and thus deregulation of glucose homeostasis
[4]. Both anesthesia techniques based on the use of either
opioids or volatile anesthetics are frequently used for the
anesthetic management of patients undergoing cardiac
operations. Furthermore, although cardiac operations neces-
sitate the use of the anti-coagulation agent heparin, it has
long been known that heparin can result in a several-fold
increase in plasma FFA levels by inducing the release of
hepatic and endothelial-bound LPL [5, 6]. This heparin-
effect is often only present during the early reperfusion phase
following by-pass operations, because heparin is usually
quickly antagonized upon termination of the by-pass. Less
well-known is the ongoing lipolysis in the sample due to the
presence of this detached LPL, especially after the in vivo
administration of heparin [7, 8]. Without special precautions,
e.g. inhibition of ex vivo lipolysis with a potent lipoprotein
lipase inhibitor [9], plasma FFA may be substantially
overestimated by the lab. We believe that this aspect has
often been neglected, resulting in an overestimation of FFA
during conditions of heparin administration (usually early
reperfusion). In addition, acute myocardial infarction in the
conscious state and post-ischemic reperfusion are character-
ized by high levels of catecholamines from endogenous
sources and/or from the inotropic support given by the
clinician [10, 11]. These high levels of catecholamines have
also been hypothesized to inhibit insulin secretion and to
activate lipolysis of adipose tissue resulting in increased
plasma FFA [12, 13].
Therefore, it appears that, in the peri-operative patient,
the standard clinical treatment and applied biochemical
determination of especially FFA are critical issues when
reviewing substrate levels during reperfusion. Each surgical/
anesthesia team should determine the metabolic profile
associated with its perioperative protocols to determine if
improvement in cardiac function may be anticipated with the
use of metabolic support. To illustrate this important point, it
is shown in Table 1 that certainly not all studies report
increased FFA and glucose levels following ischemia. The
table indicates that FFA levels are most likely to be elevated
during conditions of acute coronary syndromes in the
conscious state (e.g. acute MI, [14–16]). During conditions
of actual reperfusion, such as following PTCA after acute
MI [16–20] or after less severe ischemia, such as following
CABG in the anaesthetized condition [21–24], FFA levels
are less likely to be elevated.
It should be noted that, although elevated FFA levels
have long been viewed as a risk factor, there is evidence
that elevated glucose levels are also associated with
increased risk [25, 26]. However, the table indicates that
hyperglycemia is certainly not always present upon
reperfusion and when it is present, the rise in plasma
glucose is usually modest. An exception to this may be the
diabetic patient [24] who is more likely to develop
hyperglycemia. It therefore seems that, before embarking
on standardizing the use of insulin therapy immediately
following cardiac ischemic events on the premise of
preventing hyperglycemia and hyperlipidemia, the metabolic
profile of the patients and the clinical care treatment should
be documented. Ideally, insulin therapy should only be
given on indication of acutely monitored elevated glucose
and/or FFA plasma levels. Alternatively, in a subset of
each specific group of patients, together with the clinical
care treatment given, the metabolic profile is characterized
in terms of plasma glucose and FFA levels before a
decision is made whether the whole group of patients is
treated with insulin therapy. Only when hyperglycemia and
hyperlipidemia are present should one use insulin therapy
to combat these elevated circulating glucose and FFA
levels.
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Glucose-Insulin therapy and substrate availability
Because plasma substrate availability may limit metabolism
to a large extent [27, 28], any change in substrate
availability instigated by insulin therapy will result in shifts
in the major cellular metabolic pathways involved in the
generation of ATP, i.e., glycolysis and glucose oxidation
and fat oxidation. The administration of large amounts of
insulin will decrease circulating glucose through activation
of GLUT transporters that facilitate cellular glucose uptake
and inhibition of hepatic gluconeogenesis. The increased
risk of developing temporary periods of hypoglycemia is
one of the well-known adverse effects of insulin therapy
[29]. Insulin therapy is therefore almost always combined
with glucose administration to prevent hypoglycemia. As a
result of this increased cellular glucose uptake, glucose-
insulin therapy will increase glycolysis and glucose
oxidation. Insulin will also reduce plasma FFA concen-
trations, resulting in decreased fatty acid oxidation, promo-
tion of TAG storage and possibly hypolipidemia. This
lowering of lipids is mainly due to insulin-mediated
inhibition of the hormone-sensitive lipase in adipose tissue,
the determining enzyme for whole-body lipid fuel avail-
ability [30] and insulin-induced CD36-mediated increase in
FFA uptake [31]. Interestingly, the developing of hypolipi-
demia with glucose-insulin therapy has received far less
attention in current clinical practice as compared to
hypoglycemia [32]. This probably stems from the premise
that fatty acids are commonly believed to be elevated at
reperfusion and that any decrease in fatty acid metabolism
is always associated with improved cardiac recovery from
ischemia. However, we now know that hyperlipidemia is
not always present at reperfusion (see above), and that too
little fatty acid oxidation can be detrimental for cardiac
recovery (see below). In the following paragraphs, the
insulin-mediated changes in the three major ATP-generat-
ing pathways (increased glycolysis, increased glucose
oxidation, decreased fatty acid oxidation) are discussed in
relation to cardiac recovery from ischemia. It is well
documented that the potential usefulness of GIK certainly
also leads to non-metabolic mechanisms such as the
activation of cell survival pathways leading to cardiopro-
tection through reduction in apoptosis [33–36] and reduced
inflammatory (22) and neurohumoral responses (11).
However, in this review we focus primarily on the GIK
effects on plasma substrate levels and metabolic pathways.
Increased glycolysis
The non-oxidative breakdown of glucose to pyruvate or
lactate, i.e. glycolysis, is commonly increased in the post-
ischemic heart [37–39]. In addition, important cardiac
pathologies such as hibernation, hypertrophy and heart
failure are associated with increased glycolytic activity,
probably as a result of recurrent episodes of limited oxygen
supply [40–42]. The use of glucose-insulin therapy will
Table 1 Glucose and free fatty acid (FFA) plasma levels (mM) determined before or during ischemia (pre-reperfusion, pre-R) and at reperfusion
of the ischemic cardiac intervention as reported by several different studies
Substrate Pre-reperfusion Reperfusion Study
Glucose n.r. n.r. pre-reperfusion (pre-R): AMI patients within 24 h of MI; no
prior administration of heparin or catecholamines. [14]FFA 0.5–2.1 n.r.
Glucose 12 n.r. pre-R: AMI-patients selected with arterial FFA levels > 0.8 mM
(∽50% of MI patients); no heparin used. [15]FFA 1.2 n.r.
Glucose n.r. n.r. pre-R: ST-elevation MI < 12 h of symptom onset; R: 24 h after
PTCA of the AMI-patients; heparin n.r. [16]FFA 0.8±0.4 0.4±0.2
Glucose 7.9 6.7 pre-R: ST-elevation MI < 6 h of symptom onset; R: 24 h after
PTCA/thrombolysis of the AMI patients; heparin n.r. [17]FFA n.r. n.r.
Glucose 5.9±0.8 4.4±0.4 pre-R: baseline control dogs; R: 24 h after 3 h LAD occlusion;
heparin n.r., no inotropics. [18]FFA 0.4±0.1 0.8±0.2
Glucose 5.7±1.4 not sign.
versus pre-R
pre-R: baseline open-chest pigs; R: 30–90 min after 11 occlusions of 1–2
min of left main coronary artery; 300 IU/kg heparin, no inotropic. [19]FFA 0.4±0.2
Glucose 3.8±0.4 3.7±0.2 pre-R: baseline open-chest pigs; R: 60–90 min reperfusion after 90 min
low-flow LAD occlusion; no heparin or inotropics. [20]FFA 0.4±0.1 0.3±0.1
Glucose 9.6±2.4 8.4±2.0 pre-R: before crossclamp in 30 CABG patients; R: 10 min reperfusion;
3 mg/kg heparin, no inotropics [21]FFA 0.4±0.2 0.4±0.2
Glucose 5.5±0.5 6.3±1.0 pre-R: before crossclamp in 21 CABG patients; R: 2 h reperfusion;
no inotropics. [22, 23]FFA 0.4±0.1 0.4±0.2
Glucose 9.8±0.2 13.8±0.3 pre-R: before crossclamp in 141 diabetic CABG patients; R:
6 h reperfusion; + inotropics. [24]FFA 0.7±0.1 0.6±0.1
CABG coronary artery bypass grafting, AMI acute myocardial infarct, PTCA percutaneous transluminal coronary angioplasty, n.r. not reported
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further enhance post-ischemic glycolysis, provided that
hypoglycemia does not occur. The functional benefit of
increased glycolysis is in keeping with the observation that
the heart requires glycolysis during early reperfusion [43,
44]. Although glycolytically produced ATP only amounts
to ∽ 2% of total ATP production in the presence of oxygen,
this ATP seems to be preferentially used for membrane
functions allowing recovery of ionic homeostasis (prevent-
ing Ca2+ overload) during early reperfusion. In addition,
acidification at the moment of reperfusion may be benefi-
cial, because it inhibits mitochondrial permeability transi-
tion pore opening [45].Thus, increased glycolysis during
reperfusion is protective in conditions of recurrent ischemia
and reperfusion. However, increased glycolytic flux during
zero-flow ischemia is detrimental [46] and may result in
increased acidification during ischemia. Finally, the post-
ischemic increase in glycolysis will also slow down cellular
energy transfer [47–49] and may decrease the rate of
maximal, sustainable oxidative phosphorylation [50, 51].
It therefore seems that increasing glycolysis during
reperfusion with glucose-insulin therapy will protect against
reperfusion damage at the expense of slower energy
transfer. Because it is unlikely that delayed energy transfer
will be detrimental for the heart during acute reperfusion,
increasing glycolysis during reperfusion seems to entail an
overall protective effect against reperfusion damage.
Increased glucose oxidation
Although increased glucose oxidation is not always
observed following ischemia [27, 37, 52], most studies
have shown that the activation of glucose oxidation in the
reperfusion phase improves the recovery of cardiac perfor-
mance [53, 54]. Thus glucose-insulin therapy will be
beneficial through activation of this pathway, provided that
no hypoglycemia occurs that may actually decrease glucose
oxidation. In addition, the therapy will reduce hyperglyce-
mia, a risk factor that has been shown to contribute
independently to poor recovery [55].
Currently, the two most prevailing hypotheses explaining
the protection offered by increased glucose oxidation
involves increased mechanical efficiency and decreased
proton load, respectively. With respect to the former, it has
recently been shown that oxygen consumption for the same
amount of work increased considerably (from 10% at high
work to 48% at unloading conditions) when switching from
a predominantly glucose metabolizing condition to a
predominantly fatty acid metabolizing condition in in vivo
pigs [56]. This decreased efficiency with increased fatty
acid oxidation may be explained by a fatty acid induced
decreased P:O ratio in addition to uncoupling of oxidative
consumption and futile, energy-consuming cycling of fatty
acids in and out the intracellular triglyceride pool [56]. The
second hypothesis is associated with the so-called coupling
of glycolysis with glucose oxidation, i.e. when pyruvate
produced by glycolysis is subsequently oxidized in the
TCA cycle, the proton production from hydrolysis of
glycolytically-produced ATP is zero [27]. However, if
glycolysis is uncoupled from glucose oxidation, and
pyruvate is not oxidized further, there is a net production
of two protons from each glucose molecule metabolized.
Such may occur with increased fatty acid metabolism. Fatty
acids inhibit glucose oxidation more than glycolysis and
glycolysis more than glucose uptake, indicating that with
increasing fatty acid oxidation the rate of glycolysis
increasingly deviates from that of glucose oxidation,
resulting in the uncoupling of glycolysis from glucose
oxidation [57]. The resulting acidosis may then cause
decreased contractility and increased calcium overload
during the reperfusion period. Increased glucose oxidation
will then prevent ongoing acidosis during the early
reperfusion period, thereby improving recovery of mechan-
ical performance. However, this theory is not without
controversy. It has been shown that insulin-glucose admin-
istration in an isolated heart model improved functional
recovery compared with the administration of dichloroacte-
tae (DCA) which is a direct stimulant of carbohydrate
oxidation, whereas DCA had a greater impact on increasing
glucose oxidation [58]. In that study it was found that the
protection was not associated with increased coupling of
glucose oxidation to glycolysis. A recent study examining
mechanical recovery following low-flow ischemia in GLUT1-
overexpressed mice hearts reached similar conclusions [59].
An uniform mechanistic, cellular, explanation for the
advantageous effects of increasing glucose oxidation is
therefore currently lacking.
In general, the literature suggests that treatment aimed at
stimulation of glucose oxidation while normoglycemia is
maintained (i.e. without the concomitant development of
hyperglycemia or hypoglycemia) seems to be promising
and safe with respect to improved cardiac function in the
post-ischemic period.
Decreased fatty acid oxidation
At the moment, the prevailing opinion is that increased
fatty acid oxidation during the reperfusion period is
detrimental to the functional recovery of the heart.
However, although some studies demonstrate that increasing
FA oxidation is associated with decreased functional
recovery in the reperfusion phase [57, 60, 61] other studies
showed unaltered [62] or even improved recovery with
increased FA oxidation [37, 63]. It has been suggested that
the effects of lipids are primarily detrimental when present at
high levels during the ischemic period, but not during
reperfusion [64]. That FA oxidation during reperfusion can
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be protective is also supported by studies showing decreased
functional recovery of hearts from fatty acid transporter-
knockout animals that lack the sarcolemmal fatty acid
transporter CD36 [65], a similar observation as found for
GLUT4-knockout animals [66]. Recently, Tuunanen et al [67]
demonstrated that acute depression of plasma FFA by
acipimox, an inhibitor of lipolysis, depressed cardiac work
in healthy and diseased humans with additional decreases in
cardiac efficiency for heart failing patients. Acipimox
decreased FFA concentrations from 0.6 mM to 0.1 mM.
Interestingly, the very few studies examining the effect of
insulin therapy on FFA levels also indicate that this therapy
may reduce FFA to similar levels. Addo et al [16] reported
FFA levels of 0.2 mM with GIK therapy in patients
undergoing primary percutaneous coronary intervention (with-
out taking into account sample lipolysis). We recently
demonstrated FFA levels around 0.1 mM with insulin therapy
following CABG procedures [23]. These low FFA levels are
commensurate with the observation that FFA concentrations
are often not increased during reperfusion (see “Plasma
substrate availability during cardiac ischemic events” section
above). From these observations it may be hypothesized that
there exists a requirement for a minimal concentration of
plasma FFA for the heart in order to perform optimally. As for
glucose, the data suggest that the prevention of hypolipidemia
as well as hyperlipidemia during reperfusion may be an
important consideration of any metabolic therapy, including
the glucose-insulin therapy.
Finally, one complicating factor concerning FA effects
that may explain some of the controversy is that there are
“good” and “bad” fatty acids. Especially the saturated fatty
acids such as palmitate appear to be detrimental, even
inducing apoptosis [68], whereas other fatty acids (mainly
(poly)unsaturated fatty acids) appear to be beneficial in the
reperfusion period [69]. Future preclinical studies have to
demonstrate the potential beneficial effect of the combination
of glucose-insulin therapy with additional lipids on myocar-
dial energy balance, infarct size and mechanical function
following ischemia and reperfusion. Due to the ambiguity of
the cardiac functional effects of changes in FA metabolism,
clinically directed manipulation of FA metabolism must be
executed with great care.
Summary
In the peri-operative patient, the standard clinical treatment
and applied biochemical determination of especially plasma
FFA are critical issues when reviewing substrate levels
during reperfusion. Each surgical team should determine
the metabolic consequences of its perioperative protocol to
determine if improvement in cardiac function may be
anticipated with the use of metabolic support. FFA levels
are most likely to be elevated during conditions of acute
coronary syndromes in the conscious state (e.g. acute MI)
and less so during reperfusion post CABG. Consequently,
GIK therapy in conditions of CABG may result in
hypolipidemia that can potentially limit the beneficial effects
of this therapy. Whether hypolipidemia is disadvantageous
during post CABG reperfusion awaits further pre-clinical
and subsequently clinical studies. At the moment, monitoring
of FFA levels during GIK therapy, as is commonly
performed for glucose levels, is strongly recommended.
From a clinical point of view, a strategy directed at
monitoring and thereafter maintaining plasma substrate
levels in the normal range for (glucose 4–6 mM; FFA
0.2–0.6 mM), and at stimulation of glucose oxidation,
seems to hold the most promise for optimal metabolic
reperfusion treatment following cardiac ischemic episodes.
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